Novartis And Medicines For Malaria Venture Launch Coartem® Dispersible, The First ACT* Developed For Children Suffering From Malaria

Novartis and Medicines for Malaria Venture (MMV) announced the launch of Coartem® Dispersible, a new pediatric formulation of Coartem® (artemether/lumefantrine 20 mg/120 mg), for the treatment of uncomplicated malaria in infants and children.


Read more

Related posts

Leave a Reply